Immune Thrombocytopenic Purpura News and Research

RSS
Octapharma extends support for COVID-19 study following promising preliminary data

Octapharma extends support for COVID-19 study following promising preliminary data

FDA approves IND application by Octapharma USA for severe COVID-19 patients

FDA approves IND application by Octapharma USA for severe COVID-19 patients

Scientific evidence for and against causal associations for 47 adverse effects after immunization

Scientific evidence for and against causal associations for 47 adverse effects after immunization

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

Positive long-term outcome data for chronic ITP patients treated with rituxamab

Positive long-term outcome data for chronic ITP patients treated with rituxamab

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy